Miriam Moscovitch-Lopatin, from MassGeneral Institute for Neurodegenerative Disease presented a longitudinal pre-cell biomarker study she conducted on an ultrasensitive Simoa immunoassay for quantifying BDNF levels in cerebral spinal fluid in early Huntington's disease at the inaugural Powering P
Alison Joyce from Pfizer, Inc. presented her research on the development of a sensitive homebrew Simoa assay to detect Leucine-rich repeat Kinase 2 (LRRK2) at the inaugural Powering Precision Health Summit 2016.
TBIs are common in military personnel and civilians, placing these individuals at high risk for neurological deficits. The reasons why some individuals are at higher risk for these symptoms and deficits remains largely unknown. This webinar explores the topic further.